DeltaFLU
Universal Influenza
Phase 2Active
Key Facts
About Vivaldi Biosciences
Vivaldi Biosciences leverages its proprietary Delta NS1 platform to create intranasal, broadly protective vaccines. The platform's key innovation is the deletion of the NS1 gene, which disables viral replication and, uniquely, induces a potent local interferon response for enhanced mucosal and systemic immunity. With its lead universal flu vaccine, DeltaFLU, in Phase 2 and a combination COVID-19/flu candidate in preclinical development, Vivaldi aims to address significant unmet needs in respiratory disease prevention through a needle-free, potentially more effective vaccination strategy.
View full company profile